AcuCort AB (publ) (Spotlight Stock Market: ACUC) announced today that the company’s new website with improved functions as well as with new graphic identity and updated content has been launched.
As part of ensuring good functionality and visualizing that AcuCort takes further steps in its development, the company has developed a new website. The website now offers, for example, functions such as a subscription service for the company’s press releases and financial reports, as well as improved IR and corporate governance pages. Other content has also been updated. Please visit www.acucort.se.
”AcuCort is well on its way to taking the big step from a development company to an exciting growth company. I see good conditions for a continued positive development of the company and hope that our new website will contribute to increased interest and greater knowledge of AcuCort’s operations,” says Jonas Jönmark, CEO of AcuCort.
The information was submitted for publication, through the agency of the contact person below, on July 5, 2022.
For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
About AcuCort AB (publ)
AcuCort has developed and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented, and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). A national application was approved by the Swedish Medical Products Agency (MPA) in October 2020. In February 2021, ISICORT® was granted an additional indication – the treatment of COVID-19 patients who need supplemental oxygen treatment. Altogether, this strengthens the company’s assessment that the time to commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.se.